William Blair acted as the exclusive financial advisor to CEVEC Pharmaceuticals (CEVEC) in connection with its sale to Danaher Corporation (Danaher. NYSE: DHR) and its portfolio company Cytiva. The transaction signed and closed on October 5, 2022.
About the Companies
CEVEC is a leading provider of high-performance cell technology for the manufacturing of advanced biotherapeutics. The company’s leading viral vector manufacturing and cell line engineering platforms, including the ELEVECTA® stable producer cell line technology, are keystone technologies in the manufacturing of gene therapies. CEVEC successfully tackles one of the major challenges in scaling up gene therapies, the production of sufficient vector quantities to target diseases with larger indications.
Danaher is a NYSE-listed global science and technology investor that designs, manufactures and markets a broad range of innovative products and services with premier brand names and leading market positions to professional, life sciences, medical, industrial and commercial customers worldwide. Today, Danaher is a Fortune 200 company with revenues of about $30 billion. The company has a proven track record of acquiring exceptional companies and management teams globally, and then providing such businesses tools and capital to accelerate their growth, innovation and profitability in an autonomous manner.
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10,000 associates in more than 40 countries dedicated to customers' speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
Learn more about our biopharma investment banking expertise.